Medtronic (MDT) Tops Q2 EPS by 7c, Beats on Revenue; Raises EPS Guidance
Get Alerts MDT Hot Sheet
Revenue Growth %: +5.3%
Financial Fact:
Cost of products sold: 1.13B
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Medtronic (NYSE: MDT) reported Q2 EPS of $1.25, $0.07 better than the analyst estimate of $1.18. Revenue for the quarter came in at $8 billion versus the consensus estimate of $7.93 billion.
The company increased its FY24 diluted non-GAAP EPS guidance from the prior range of $5.08 to $5.16 to the new range of $5.13 to $5.19, a 4 cent increase at the midpoint. Given the change in foreign currency exchange rates over the past quarter, the foreign exchange impact on FY24 diluted non-GAAP EPS is now estimated to be 2 cents more unfavorable in the second half and is estimated to be a 6% unfavorable impact for the full year.
For earnings history and earnings-related data on Medtronic (MDT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Casey's General Stores (CASY) Tops Q1 EPS by 69c
- lululemon athletica (LULU) Tops Q2 EPS by $1.10, Cuts Guidance
- United Natural Foods (UNFI) Tops Q4 EPS by 8c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, Guidance, Hot Earnings, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share